Hormonal
GLP-1 therapy is associated with significant gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) which are dose-dependent and can lead to discontinuation, although most side effects decrease with continued use.
You will likely experience some gastrointestinal side effects like nausea, diarrhea, or constipation, especially when you start the medication or increase the dose. These symptoms often improve over time. Talk to your doctor about managing these side effects through diet and slow dose titration.
GI side effects are most frequent and include nausea (25–44 %), diarrhea (19–30 %), vomiting (8–24 %), constipation (17–24 %), and abdominal pain (9–20 %) [39–44]. ... Higher doses are more likely to provoke these adverse symptoms, indicating a dose-dependent relationship [38].
Why this rating
Consistently reported across multiple trials and real-world studies.
Source
Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
Dariush Mozaffarian et al. · Obesity Pillars · 2025
DOI 10.1016/j.obpill.2025.100181
More from this paper
- Discontinuation of GLP-1 therapy leads to rapid and substantial weight regain, often returning to near baseline levels within one year, highlighting the chronic nature of obesity treatment.Strong
- GLP-1 receptor agonists for obesity treatment cause significant loss of lean body mass (approximately 20-25% of total weight reduction in men and 10-15% in women) and bone density, particularly when rapid weight loss occurs without structured resistance training.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →